Skip to main content

Roche and Novartis among global leaders for research spending

| News

Roche and Novartis among global leaders for research spending


In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in 8th place worldwide. For its part, Novartis is ranked 14th, making it the second-highest ranking Swiss firm in the top 500.

In total, 14 Swiss companies are ranked in the group of 500 companies worldwide with the highest level of corporate expenditure for research and development (R&D), further details of which can be found in a press release issued by EY. With Roche ranked in 8th position overall, Switzerland is even represented in the top ten. Overall, the Basel-based pharmaceutical company invested the equivalent of 16 billion euros in R&D activities in 2022.

With Novartis in 14th position, the second-highest ranked Swiss firm also comes from Basel. The life sciences company spent the equivalent of 9.5 billion euros on R&D. At 159 million euros, the specialist chemicals firm Clariant from Muttenz in the canton of Basel-Landschaft was ranked in 454th place, making it the third Basel Area company in the top 500. The Swiss delegation is rounded off by STMicroelectronicsNestléABBTE ConnectivityAlcon IncGivaudanThe Swatch GroupSwisscomSikaHolcim and Schindler Holding, which are ranked between 103rd and 420th.

Swiss companies invested 33 billion euros in R&D

Measured by the number of companies, Switzerland is more or less on a par with the UK, the press release explains. “This is an expression of the strength of Switzerland as a research location”, Stefan Rösch-Rütsche, Country Managing Partner of EY in Switzerland, who concludes that this can in particular be attributed to “the availability of human resources in research and development and the proximity to the world’s leading technical universities”.

All in all, Swiss companies invested the equivalent of 33 billion euros in R&D activities overall in 2022. This puts Switzerland in 5th place in a global comparison. For Rösch-Rütsche, this is “a positive sign for Switzerland as a business location”. However, he also points out that investments in Switzerland have increased by just +5 percent, which is well below the global average of +14 percent.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.